Evidence map›Paper›PMID 39528799›Full record

ArticleNPJ precision oncology2024

Benchmark of screening markers for KEAP1/NFE2L2 mutations and joint analysis with the K1N2-score.

Christoph Arolt, Andreas H Scheel, Margaret Dugan, Robert Wild, Vanessa Richartz, Barbara Holz, Johannes Brägelmann, Svenja Wagener-Ryczek, Sabine Merkelbach-Bruse, Juergen Wolf and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. TheCancer management and research · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Christoph Arolt *Institute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Andreas H Scheel *Institute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Margaret DuganDracen Pharmaceuticals Inc., San Diego, CA, USA.
Robert WildDracen Pharmaceuticals Inc., San Diego, CA, USA.ORCID http://orcid.org/0000-0001-9182-3587
Vanessa RichartzInstitute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Barbara HolzInstitute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Johannes BrägelmannInstitute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Svenja Wagener-RyczekInstitute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Sabine Merkelbach-BruseInstitute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Juergen WolfLung Cancer Group Cologne, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.
Reinhard BuettnerInstitute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0001-8806-4786
Luigi CatanzaritiDracen Pharmaceuticals Inc., San Diego, CA, USA.
Matthias Scheffler *Lung Cancer Group Cologne, Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany. matthias.scheffler@uk-koeln.de.ORCID http://orcid.org/0000-0002-9031-1368
Axel M Hillmer *Institute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. ahillmer@uni-koeln.de.ORCID http://orcid.org/0000-0002-3381-7266

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) 413326622Deutsche Forschungsgemeinschaft (German Research Foundation) 418074181Deutsche Forschungsgemeinschaft (German Research Foundation) 446411360Deutsche Krebshilfe (German Cancer Aid) 70113307
6 · The paper itself

Abstract

Our recently published K1N2-score robustly predicts KEAP1/NFE2L2-mutations and pathway activation status, while its accessibility might be limited. We tested if the RNA expression data of six pathway-related genes and NQO1-IHC might be a reliable alternative using 348 KEAP1/NFE2L2 mutation-enriched NSCLC. While TXNRD1 RNA testing was the best-performing single-gene test, the combination of single-gene screening and validation with the K1N2-score achieved the highest performance when predicting mutation status or pathway activation.

Identifiers

PMID39528799
PMCPMC11554772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.